| Document |
Document Title |
|
WO/2024/030962A3 |
Compositions are provided containing at least one mRNA sequence encoding a mutant soluble human Ace2 (hAce2) protein useful in preventing infection with betacoronaviruses, including SARS-CoV2 is provided, as are compositions useful in tr...
|
|
WO/2024/036105A3 |
A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cel...
|
|
WO/2024/086741A2 |
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the...
|
|
WO/2024/083870A1 |
There is provided an Aβ peptide binding polypeptide, which comprises an amino acid sequence selected from i) and ii), wherein: i) is SEQ ID NO:1 – [LINK] – SEQ ID NO:2; ii) is SEQ ID NO:3 – [LINK] – SEQ ID NO:4; and [LINK] is a ...
|
|
WO/2024/086791A2 |
Provided herein at chimeric receptors comprising an IgG Fc receptor and toll/interleukin- 1 receptor (TIR) signaling domain. Further provided are immune effector cells (e.g., NK cells) expressing said chimeric receptors and methods for u...
|
|
WO/2023/230598A3 |
Disclosed are methods of producing recombinant feline morbillivirus (FeMV) using reverse genetics. In some aspects, the methods comprise: (a) extracting FeMV RNA from an isolated FeMV positive sample, (b) generating cDNAs from the FeMV R...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
|
WO/2024/015877A9 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these cap...
|
|
WO/2024/086802A1 |
In one aspect, the present disclosure describes methods which may be used to purify target proteins from sample mixtures. The methods disclosed herein may also be used to purify or sort cells from sample mixtures.
|
|
WO/2024/084785A1 |
The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine. Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus,...
|
|
WO/2024/050464A3 |
Described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of ischemia-reperfusion injury in a subject using GJA1-20k as a therapeuti...
|
|
WO/2024/086530A1 |
Described herein are chocolate compositions comprising sweet proteins, such as sweet polypeptides (e.g., brazzein, brazzein-53, brazzein-54, or a combination of brazzein-53 and brazzein-54), and method of producing the same.
|
|
WO/2024/084441A1 |
The present disclosure provides methods, compositions, and kits for the treatment or prevention of an HIV infection in a human having or at risk of having HIV, comprising the combination of the HTI immunogen and at least one stable solub...
|
|
WO/2024/040072A3 |
Various peroxidases are useful in treating subjects suffering from diseases associated with buildup of bisretinoids. The disclosed peroxidases may also be useful in activating prodrugs. The disclosed peroxidases may be administered as ma...
|
|
WO/2024/085671A1 |
The present application relates to a mutant ribonuclease activity regulating protein and a method for producing L-valine using same.
|
|
WO/2024/086298A2 |
Provided herein are HLA-class I and HLA-class II restricted and non-restricted epitopes recurrently identified in patients with cancer, that can be presented to T cell receptor (TCR) to induce polyfunctional T cell response, polyepitopes...
|
|
WO/2024/083224A1 |
The present invention discloses compounds of Formula (I) and their complexes with radionuclides that can recognize both Somatostatin type 2 receptor (SSTR2) and cholecystokinin 2 receptor (CCK2R) and can be used in the diagnosis and trea...
|
|
WO/2024/057094A3 |
Human interleukin-2 (IL-2) muteins or variants thereof are provided. Also provided are pharmaceutical compositions that include such IL-2 muteins.
|
|
WO/2024/086842A2 |
The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising a first antigen-recognizing receptor (e.g., a chimeric antigen receptor ...
|
|
WO/2024/086557A1 |
Methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
|
|
WO/2024/086683A2 |
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be s...
|
|
WO/2024/085533A1 |
The present invention pertains to: a composition for improving the efficiency of introducing vectors into cells by using lunasin; and a method for introducing vectors into cells with high efficiency by using said composition.
|
|
WO/2024/086190A1 |
The disclosure relates to chimeric antigen receptor (CAR) specific to CD 19, vectors encoding the same, and recombinant T cells comprising the CD 19 CAR. The disclosure also includes methods of administering a genetically modified T cell...
|
|
WO/2024/044691A3 |
Disclosed herein are compositions comprising chemically modified adeno-associated viruses (AAV) engineered by chemical modification of capsid proteins, whether wildtype or engineered, and methods of using such modified AAVs for therapeut...
|
|
WO/2024/083226A1 |
An activatable antibody fusion protein, said fusion protein comprising an antibody portion specifically binding to a target, an immunoglobulin Fc portion, a masking portion and a cytokine portion. The present invention further relates to...
|
|
WO/2024/044725A3 |
The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences that confer and/or enhance desired properties. In particular, the invention provides engineer...
|
|
WO/2024/059630A3 |
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprisi...
|
|
WO/2023/212658A3 |
Provided herein are compositions and methods for the treatment of infectious diseases including COVID and Long COVID. The compositions and methods can be used to treat symptoms relating to infectious disease infection or vaccination as w...
|
|
WO/2024/015922A3 |
The present invention relates generally to novel multi-agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control of weight loss, plasma gl...
|
|
WO/2024/083988A1 |
The present disclosure provides single domain antibodies (VHH or nanobodies) and conjugates thereof which are able to inhibit binding between PD-L1 and PD-1 with high efficiency. The disclosure additionally refers to viral vectors compri...
|
|
WO/2024/020543A3 |
The present disclosure features kits and methods for diagnosis and treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells. The methods include using a mixture of lytic enzymes to specifically...
|
|
WO/2024/083912A1 |
The present invention relates to YGHJ polypeptides with novel glycosylation patterns. The glycosylated polypeptides are expressed in an avirulent genetically altered strain of the natural pathogenic bacteria, which gives rise to glycosyl...
|
|
WO/2024/085480A1 |
The present invention relates to: lactic acid bacteria extracellular membrane protein PrsA having a cell surface display anchor motif function; and a vector system for cell surface display of a target protein, the system comprising a seq...
|
|
WO/2024/084432A1 |
Provided are recombinant fusion proteins and compositions and uses thereof, the recombinant fusion protein including an interleukin-2 mutein and an antigen-binding fragment to serum albumin. The recombinant fusion protein has the advanta...
|
|
WO/2024/086191A2 |
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL...
|
|
WO/2024/082178A1 |
Provided is a chimeric antigen receptor, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain targets CD19, and the second antigen-binding domain targets CD22. Also provi...
|
|
WO/2024/086747A1 |
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistributi...
|
|
WO/2024/086680A2 |
The present invention relates to Atrial Natriuretic Peptide (ANP) polypeptides and methods of treatment with ANP polypeptides.
|
|
WO/2024/086169A2 |
Novel compositions of TCR Gamma Alternate Reading Frame Protein (TARP) peptides combined with cationic lipids such as the DOTAP and specifically R-DOTAP, induce high levels of TARP-specific polyfunctional cytolytic T-cells. Compositions ...
|
|
WO/2024/082795A1 |
The present invention relates to a protein and a vaccine against infections of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, which belong to the field of medicines. In order to solve the problem of lack of effective prevent...
|
|
WO/2024/086549A1 |
This invention relates chimeric alphavirus genomes, alphavirus particles and compositions comprising the same, and their use in methods of directed evolution, such as methods of modify a heterologous nucleic acid, evolving a heterologous...
|
|
WO/2024/084054A1 |
The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, each segment being operably linked t...
|
|
WO/2024/084497A1 |
The present disclosure relates to manufacturing transferrin binding proteins. Specifically, the present disclosure relates to a simple, scalable, commercially viable fermentation and purification process for obtaining recombinant transfe...
|
|
WO/2024/083973A1 |
The present invention relates to a host cell. The host cell finds utility as a biosensor by comprising at least one nucleic acid modification in the nucleic acid sequence of at least one gene. Also disclosed is the host cell for use as a...
|
|
WO/2024/086290A2 |
Provided herein are multiepitope peptides including at least one mucin 1 (MUC1) peptide, the multiepitope peptides have MHC affinity for at least one of HLA serotype and are recognized by a CD4+ T cell receptor and/or by a CD8+ T cell re...
|
|
WO/2024/082005A1 |
The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising the...
|
|
WO/2024/086628A2 |
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with increased transduction enrichment in the brain and, in some cases, reduced transduction in the liver. The rAAV compositions describe...
|
|
WO/2024/086171A1 |
The present invention provides a bone graft such as an allograft and a method for releasing growth factors from tissues (e.g., bone marrow, bone matrix, periosteum, and/or endosteum) having native living cells. Also provided are a compos...
|
|
WO/2024/084082A1 |
The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of...
|
|
WO/2024/086781A2 |
According to some aspects, systems and methods for characterizing phosphoserine-containing polypeptides are described. In some embodiments, a phosphoserine residue of a polypeptide may be converted to a dehydroalanine residue. Some aspec...
|
